Images are for illustrative purposes only.

Cagrilintide

Cagrilintide (development code AM833) is a long-acting amylin analogue, supplied as unformulated lyophilized peptide for laboratory research. It is built on the 37-amino-acid amylin scaffold with substitutions that block amyloid aggregation, and carries a C18 fatty-diacid chain that enables albumin binding and a reported plasma half-life on the order of seven days.

Unlike the selective next-generation analogues, cagrilintide is a broad amylin receptor agonist: it engages amylin receptor subtypes together with the calcitonin receptor, which is why it is commonly described as a dual amylin and calcitonin receptor agonist. That receptor coverage is the main point of contrast with the selective AMY1 agonist eloralintide. In vitro research examines receptor binding kinetics, amylin and calcitonin receptor activation, gastric-motility signaling, and central appetite regulation, frequently in combination models alongside GLP-1 receptor agonists such as semaglutide, the pairing studied as CagriSema.

Supply and format: cagrilintide is offered in two vial sizes, 5 mg and 10 mg, each as a 10-vial kit (50 mg or 100 mg total peptide). Material is lyophilized, tested to ≥99% purity by HPLC with molecular identity confirmed by mass spectrometry, and a certificate of analysis is available on request. Cagrilintide is investigational and has not been approved by any regulatory authority. For in vitro research use only.